Industrial Psychiatry Journal

CASE REPORT
Year
: 2022  |  Volume : 31  |  Issue : 1  |  Page : 158--161

Aripiprazole-induced obsessive–compulsive symptoms


Dilshana Nafisa, Anil Kakunje 
 Department of Psychiatry, Yenepoya Medical College, Mangalore, Karnataka, India

Correspondence Address:
Dr. Dilshana Nafisa
Department of Psychiatry, Yenepoya Medical College, Deralakatte, Mangalore - 575 018, Karnataka
India

Aripiprazole is a novel antipsychotic with a unique pharmacological profile as a dopamine partial agonist.It is indicated for treatment of schizophrenia and bipolar disorder. This new antipsychotic has low rate of extrapyramidal side effects, metabolic changes and no significant adverse effect on serum prolactin concentration. In addition,it is not associated with significant weight gain like other atypical antipsychotics. As a reason, when other antipsychotics cause these adverse events, it's not uncommon to switch to Aripiprazole.Obsessive compulsive symptoms have been untoward sequel of a few second-generation antipsychotics. Among the second generation antipsychotics Clozapine, Olanzapine, and Risperidone are the most prominent agents associated with these sequelae, according to case reports. More recently, a handful of case reports indicated development of Obsessive-compulsive symptoms with Aripiprazole. We report a case that exhibited similar unexpected adverse effects after administration of Aripiprazole. Keywords: Aripiprazole, Second generation antipsychotics, Obsessive-compulsive symptoms (OCS).


How to cite this article:
Nafisa D, Kakunje A. Aripiprazole-induced obsessive–compulsive symptoms.Ind Psychiatry J 2022;31:158-161


How to cite this URL:
Nafisa D, Kakunje A. Aripiprazole-induced obsessive–compulsive symptoms. Ind Psychiatry J [serial online] 2022 [cited 2022 Aug 18 ];31:158-161
Available from: https://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2022;volume=31;issue=1;spage=158;epage=161;aulast=Nafisa;type=0